B Wesley Trotter

USPTO Granted Patents = 29 (Patent Applications = 1)

EPO Patents = 14 (Patent Applications = 6)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 39(Granted Patents)

Location History:

Glenside, NJ (US) (2010)
Newton Highland, MA (US) (2013)
Newton Highlands, MA (US) (2013 - 2016)
Glenside, PA (US) (2008 - 2018)
Medfield, MA (US) (2014 - 2020)

Company Filing History:

26 out of 2,405

Merck Sharp + Dohme Corp.

Sumitomo Dainippon Pharma Co., Ltd.

patents

5. 1 out of 4

Merch Sharp & Dohme Ltd

patents

where one patent can have more than one assignee

Years Active: 2008-2020

where 'Filed Patents' based on already Granted Patents

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10689369 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2020-06-23),

2. 10584121 - Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof (2020-03-10),

3. 10344000 - Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-07-09),

4. 10287272 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2019-05-14),

5. 9867821 - Hexahydro-1H-4,7-methanoisoindole-1,3-dione compounds (2018-01-16),

6. 9682978 - 2,6,7 substituted purines as HDM2 inhibitors (2017-06-20),

7. 9637493 - Substituted pyrrolopyrimidines as HDM2 inhibitors (2017-05-02),

8. 9540377 - 2,6,7,8 substituted purines as HDM2 inhibitors (2017-01-10),

9. 9309199 - Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders (2016-04-12),

10. 9024032 - Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders (2015-05-05),

11. 8962611 - Substituted imidazopyridines as HDM2 inhibitors (2015-02-24),

12. 8846657 - Substituted imidazopyridines as HDM2 inhibitors (2014-09-30),

13. 8551984 - Aminopyrimidines as SYK inhibitors (2013-10-08),

14. 8541595 - Imidazoisoindole neuropeptide S receptor antagonists (2013-09-24),

15. 8410111 - Hexahydro-1H-4,7-methanoisoindole-1,3-dione compounds (2013-04-02),

Title: Unveiling the Inventive Genius of B Wesley Trotter

Introduction:

In the realm of innovation and patent accomplishments, B Wesley Trotter stands as a beacon of creativity and success. Hailing from Glenside, PA, with an impressive portfolio of 29 patents, Trotter's contributions have made significant waves in the field of pharmacology.

Latest Patents:

Trotter's latest patents showcase his expertise and focus on pharmaceutical advancements. His creations, such as the Substituted Indazole Compounds and Heteroaryl Substituted Benzoic Acids as RORgammaT Inhibitors, highlight his commitment to developing treatments for RORgammaT-mediated diseases.

Career Highlights:

Having worked with renowned companies like Merck Sharp & Dohme Corporation and Merck & Company, Inc., Trotter has honed his skills and expertise in the pharmaceutical industry. His innovative approach and dedication to research have propelled him towards groundbreaking discoveries.

Collaborations:

Throughout his career, Trotter has collaborated with esteemed professionals in the field. Partnerships with individuals like Kausik K Nanda and Mark T Bilodeau have not only enriched his work but also led to the development of impactful solutions in pharmacology.

Conclusion:

In conclusion, B Wesley Trotter's journey as an inventor is a testament to his unwavering commitment to innovation and scientific advancement. His patents, collaborations, and career highlights underscore his invaluable contributions to the field of pharmaceutical research, shaping the landscape of RORgammaT-mediated disease treatments.

This text is generated by artificial intelligence and may not be accurate.